» Articles » PMID: 29449315

Metaplastic Breast Cancer in a Patient with Neurofibromatosis Type 1 and Somatic Loss of Heterozygosity

Overview
Specialty Genetics
Date 2018 Feb 17
PMID 29449315
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Metaplastic breast carcinoma (MBC) is rare and has a poor prognosis. Here we describe genetic analysis of a 41-yr-old female patient with MBC and neurofibromatosis type I (NF1). She initially presented with pT3N1a, grade 3 MBC, but lung metastases were discovered subsequently. To identify the molecular cause of her NF1, we screened for germline mutations disrupting or , revealing a heterozygous germline single-nucleotide variant (SNV) in exon 21 of at c.2709G>A, Chr 17: 29556342. By report, this variant disrupts pre-mRNA splicing of transcripts. No pathogenic mutations were identified in A potential association between MBC and NF1 was reported in eight previous cases, but none underwent detailed genomics analysis. To identify additional candidate germline variants potentially predisposing to MBC, we conducted targeted exome sequencing of 279 established cancer-causing genes in a control blood sample, disclosing four rare SNVs. Analysis of her breast tumor showed markedly altered variant allelic fractions (VAFs) for two (50%) of them, revealing somatic loss of heterozygosity (LOH) at germline SNVs. Of these, only the VAF of the pathogenic SNV in was increased in the tumor. Tumor sequencing demonstrated five somatic mutations altering , , and other genes potentially contributing to cancer formation. Because somatic LOH at certain germline SNVs can enhance their impacts, we conclude that increased allelic imbalance of the pathogenic SNV in likely contributed to tumorigenesis. Our results highlight a need to assess predisposing genetic factors and LOH that can cause rare, aggressive diseases such as MBC in NF1.

Citing Articles

Pathogenic Germline Variants in Patients With Metaplastic Breast Cancer.

Demarest K, Anantharajah A, Maxwell K, Rohanizadegan M, Bradbury A, Nathanson K JAMA Netw Open. 2025; 8(2):e2460312.

PMID: 39964682 PMC: 11836754. DOI: 10.1001/jamanetworkopen.2024.60312.


A Comprehensive Overview of NF1 Mutations in Iranian Patients.

Savad S, Modarressi M, Younesi S, Seifi-Alan M, Samadaian N, Masoomy M Neuromolecular Med. 2024; 26(1):28.

PMID: 38954284 DOI: 10.1007/s12017-024-08790-5.


Germline pathogenic variants in metaplastic breast cancer patients and the emerging role of the BRCA1 gene.

Corso G, Marabelli M, Calvello M, Gandini S, Risti M, Feroce I Eur J Hum Genet. 2023; 31(11):1275-1282.

PMID: 37460658 PMC: 10620155. DOI: 10.1038/s41431-023-01429-2.


Dynamic contrast-enhanced MRI and sequential CT findings of metaplastic breast carcinoma in neurofibromatosis type 1: A case report.

Ando S, Ito S, Kawabata K, Kanagaki M, Hijikata Y, Kiso M Radiol Case Rep. 2023; 18(6):2224-2228.

PMID: 37123039 PMC: 10139865. DOI: 10.1016/j.radcr.2023.03.039.


Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.

Gonzalez-Martinez S, Perez-Mies B, Carretero-Barrio I, Palacios-Berraquero M, Perez-Garcia J, Cortes J Cancers (Basel). 2020; 12(7).

PMID: 32650408 PMC: 7408634. DOI: 10.3390/cancers12071832.


References
1.
Barnes P, Boutilier R, Chiasson D, Rayson D . Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/neu expression. Breast Cancer Res Treat. 2005; 91(2):173-8. DOI: 10.1007/s10549-004-7260-y. View

2.
Huson S, Harper P, Compston D . Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988; 111 ( Pt 6):1355-81. DOI: 10.1093/brain/111.6.1355. View

3.
Lakshmaiah K, Kumar A, Purohit S, Viveka B, Rajan K, Zameer M . Neurofibromatosis type I with breast cancer: not only for women!. Hered Cancer Clin Pract. 2014; 12(1):5. PMC: 3974064. DOI: 10.1186/1897-4287-12-5. View

4.
Brasfield R, Das Gupta T . Von Recklinghausen's disease: a clinicopathological study. Ann Surg. 1972; 175(1):86-104. PMC: 1355163. DOI: 10.1097/00000658-197201000-00015. View

5.
Walker L, Thompson D, Easton D, Ponder B, Ponder M, Frayling I . A prospective study of neurofibromatosis type 1 cancer incidence in the UK. Br J Cancer. 2006; 95(2):233-8. PMC: 2360616. DOI: 10.1038/sj.bjc.6603227. View